Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer

Trial ID or NCT#

NCT03422198

Status

recruiting iconRECRUITING

Purpose

This randomized phase III trial studies short course vaginal cuff brachytherapy to see how well it works compared with standard of care vaginal cuff brachytherapy in treating participants with stage I-II endometrial cancer. Short course vaginal cuff brachytherapy, also known as internal radiation therapy, uses (over a shorter period) radioactive material placed directly into or near a tumor in the upper portion of the vagina to kill tumor cells. After completion of cohort 1 (108 participants), the protocol was expended to add a second cohort of 80 additional participants, and re-opened study recruitment.

Official Title

Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care (SAVE)

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. * Histologically confirmed endometrial carcinoma: endometrioid type, serous, and clear cell, to include tumors originating in the cervix, but are primarily located in the uterus, and for whom vaginal cuff brachytherapy is indicated. Carcinosarcoma and other sarcomas are permitted; Federation of Gynecology and Obstetrics (FIGO) stage I, with one of the following combinations of stage and grade:
  2. * Stage IA, grade 2, 3 * Stage IB, grades 1-3 * Stage II, grades 1-3 * Stage IIIA, grades 1-3, not receiving EBRT as part of adjuvant therapy.* Participants post hysterectomy and free from residual disease.* World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG)-performance status 0-2.* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.* Life expectancy of \>2 years.
Exclusion Criteria:
  1. * Stages of endometrial carcinoma other than described.* Previous pelvic radiotherapy.* Interval between the hysterectomy and planned start of radiotherapy exceeding 16 weeks.

Investigator(s)

Elizabeth Kidd
Elizabeth Kidd
Radiation oncologist
Professor of Radiation Oncology (Radiation Therapy)

Contact us to find out if this trial is right for you.

Contact

Akschy Peer
650-736-0792